2024-10-13 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1. Performance Comparison:**

Johnson & Johnson (JNJ) is a multinational pharmaceutical, medical device, and consumer packaged goods company.  

JNJ's cumulative return of 34.75% significantly lags behind the S&P 500 (VOO) at 135.82%. The current relative divergence is -101.07, meaning JNJ has underperformed the S&P 500 by a significant margin, falling within the bottom 3.93% of its historical performance range. 

**2. Recent Price Movement:**

* **Closing price:** 161.46
* **5-day moving average:** 160.36
* **20-day moving average:** 162.36
* **60-day moving average:** 161.75

JNJ is trading slightly below its 20-day moving average but above its 5-day and 60-day moving averages, suggesting potential short-term volatility.

**3. Technical Indicators:**

* **RSI:** 41.54 - This indicates the stock is currently in neutral territory, neither overbought nor oversold.
* **PPO:** -0.15 - A negative PPO value indicates a potential short-term downtrend.
* **Delta_Previous_Relative_Divergence:** -8.37 - This negative value suggests recent short-term underperformance compared to the S&P 500.
* **Expected Return:** 0.0% -  This indicates the current expected return for the next five years based on its past performance, while considering the S&P 500 as a benchmark. It suggests potential for a lower return compared to the benchmark, but with a lower risk profile.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-07-25 | 1.95 | 22.45 B$ |
| 2024-05-01 | 1.35 | 21.38 B$ |
| 2024-02-16 | 1.68 | 21.39 B$ |
| 2023-10-27 | 10.32 | 21.35 B$ |
| 2024-02-16 | 10.32 | 21.35 B$ |

JNJ's most recent earnings report (2024-07-25) showed an EPS of 1.95 and revenue of 22.45 Billion dollars. This represents a significant increase from the previous quarter, suggesting strong performance and revenue growth. However, investors need to consider the impact of the upcoming spinoff of the Consumer Health business on future earnings.

**5. News and Recent Issues:**

The recent market outlook for JNJ remains positive, with analysts highlighting the company's strong position in the pharmaceutical and medical device sectors. The impending spinoff of the Consumer Health business has garnered much attention. While some analysts believe the move could benefit both JNJ and the newly independent consumer health company, others express concerns about the potential impact on growth and profitability. 

**6. Overall Analysis:**

JNJ exhibits a mixed outlook. Despite a strong recent earnings report, the stock has significantly underperformed the S&P 500, with a low expected return. The impending spinoff of the Consumer Health business introduces uncertainty and potential market volatility. While the company holds a robust position in the pharmaceutical and medical device sectors, investors should carefully consider the potential risks and opportunities associated with the spinoff and the company's overall growth trajectory. 

**7. Recommendation:**

JNJ presents an interesting investment opportunity for investors seeking a blend of stability and potential growth. While the stock has recently lagged behind the market, its strong core businesses, dividend-paying history, and potential for long-term value creation make it an attractive option. However, investors should remain aware of the risks associated with the impending spinoff and carefully assess their individual risk tolerance and investment goals before making a decision. 
